Full-Time

Associate – Warehouse Operations and Materials Handling

Posted on 9/25/2023

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Mid

North Bethesda, MD, USA

Required Skills
Communications
Management

You match the following Arcellx's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • At least 3 years of experience in health care industry / supply chain / warehousing
  • ERP system experience/knowledge is required with emphasis on materials management and supply chain modules and functions
  • Strong command of Excel, Power Point, and other Microsoft applications
  • Knowledge of supplier management, planning and storage monitoring, and delivery and dispatch of orders
  • High attention to detail and written procedure compliance with understanding of safety protocols and requirements
  • Process improvement and change management experience is preferred
  • Demonstrated organizational and planning skills
  • Must act with integrity, be customer-centric and results-oriented
  • Strong English oral and written communications with excellent interpersonal and collaboration skills
  • Ability to bend and lift heavy loads
Responsibilities
  • Oversee receiving, verification, unpacking, and distribution of lab materials
  • Ensure that all materials coming into and out of designated Arcellx facilities are appropriately tracked, recorded, and compliant
  • Review and complete transactions in the ERP system to ensure all system transactions (receiving, returns, transfers, etc) are accurate and invoices are paid on time
  • Manage on-site Kanban inventory system to ensure consistent supply
  • Review, coordinate, and schedule inventory replenishments from off-site warehouse
  • Coordinate, pack, schedule, and troubleshoot outbound partner and laboratory shipments and returns, including temperature sensitive materials
  • Maintain pack out supplies including packaging materials, data loggers, etc., and supplier-managed shared materials (dry ice, liquid nitrogen, O2, etc.)
  • Support inventory controls through physical counts, inventory tracking, communication, investigations of discrepancies, and reconciliations with data storage systems as required
  • Ensure compliance with local or regional warehousing, material handling, and shipping requirements and Protected Health Information (PHI)
  • Support front office operations as required
Desired Qualifications
  • Process improvement and change management experience
  • Experience in the healthcare industry
  • Knowledge of safety protocols and requirements
  • Organizational and planning skills
  • Strong English oral and written communications
  • Interpersonal and collaboration skills

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary immunotherapy products and has a business model that includes research, development, and commercialization, generating revenue through partnerships and licensing agreements. The goal of Arcellx is to meet unmet medical needs by creating safe and effective treatment options.

Company Size

51-200

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
  • Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.
  • Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
  • Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.
  • Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
  • The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
  • ARC-SparX offers dosable and controllable CAR-T therapy options.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

3%
Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Yahoo Finance
Mar 2nd, 2024
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.

PRWeek
Feb 7th, 2024
PR Week Global

Biotech Arcellx promotes Myesha Lacy to chief investor and comms officer | PR Week

Zacks Investment Research
Dec 15th, 2023
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

The partnership with Arcellx was recently expanded to develop CART-ddBCMA to treat lymphomas.

INACTIVE